SCHEMBL4850437

SCHEMBL4850437

CCOP(=O)(Cc1nc(N2CCN(C(=O)OC(C)(C)C)CC2)sc1C)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.42
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2C19 P33261 1/20 0.36
GBA1 P04062 1/20 0.36
HTT P42858 2/20 0.36
ATM Q13315 1/20 0.36
MAPT P10636 4/20 0.36
TSHR P16473 2/20 0.36
TP53 P04637 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
ACKR3 P25106 1/20 0.35
LMNA P02545 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MAPK1 P28482 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850288 0.81 PPARG (0.46) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL27413265 0.81 PPARG (0.44) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL7920834 0.80 PPARG (0.49) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL7914512 0.78 PPARG (0.46) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL4850285 0.77 DPP4 (0.47) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL19056939 0.74 CKS1B (0.44) PPARGCKS1BSKP1SKP2SMN1; SMN2
SCHEMBL13209772 0.73 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL4885583 0.71 MEN1 (0.48) PPARGSMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL16075308 0.71 MAPT (0.43) CKS1BSKP1SKP2SMN1; SMN2MEN1
SCHEMBL27711575 0.70 CKS1B (0.61) PPARGCKS1BSKP1SKP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885CKS1B 3255/4885SKP1 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.